Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.

bioRxiv : the preprint server for biology·2026

Same author

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026

Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026

Same author

Contemporary Perioperative Outcomes of Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Journal of endourology·2026

Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026

Same author

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.

JAMA internal medicine·2026

Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 7, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.

Kelvin A Moses¹, Preston C Sprenkle², Clinton Bahler³

¹Vanderbilt-Ingram Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN

|March 10, 2023

Summary

This summary is machine-generated.

The National Comprehensive Cancer Network (NCCN) updated prostate cancer early detection guidelines. Updates focus on testing protocols, multiparametric MRI use, and managing negative biopsies to improve detection of significant cancers.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Aug 7, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Area of Science:

Urology
Oncology
Medical Guidelines

Background:

Prostate cancer early detection programs aim to identify clinically significant disease.
Informed decision-making requires understanding the benefits and drawbacks of screening.

Purpose of the Study:

To summarize recent updates to the NCCN Guidelines for Prostate Cancer Early Detection.
To optimize the detection of clinically significant prostate cancer.
To minimize the detection of indolent prostate cancer.

Main Methods:

Review of recent updates to the NCCN Guidelines.
Focus on testing protocols, multiparametric MRI (mpMRI), and negative biopsy management.

Main Results:

Revised recommendations for prostate cancer screening protocols.
Inclusion of multiparametric MRI in the diagnostic pathway.
Updated strategies for managing patients with negative biopsy results.

Conclusions:

The updated NCCN guidelines aim to enhance the accuracy of early prostate cancer detection.
These revisions support better differentiation between aggressive and indolent forms of the disease.
Optimized protocols assist clinicians in managing prostate cancer screening effectively.